Sales of blockbuster Pfizer drug Xeljanz are under pressure from a stronger safety warning placed across that drug’s entire class. In acquiring Arena Pharmaceuticals for $6.7 billion, Pfizer gets a lead compound with a different and potentially safer approach to treating inflammatory conditions.
The voluntary withdrawal was in response to an FDA request. Eisai said its interpretation of the data differed from the agency's, but the drug's original developer had called off pursuit of European approval when regulators there pointed to potential tumor risk from long-term use.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Ten months in, CEO of Arena Pharmaceuticals Amit Munshi has made some radical changes to the fragmented company, pulling away from its flagship weight loss drug to focus on the clinical pipeline.
The U.S. Food and Drug Administration’s move to approve the first obesity drug in 13 years seems to reflect a calculated risk by the regulator that the health hazards associated with weight loss drugs are eclipsed by the urgency of escalating medical costs associated with widespread obesity in the country. The healthcare costs associated with […]
Though presumptive House Speaker John Boehner (R-Ohio) says of health reform, "there's a lot of tricks up our sleeves in terms of how we can dent this, kick it, slow it down to make sure it never happens," it is likely the law will remain intact in a divided Congress, according to the Washington Post.
The Food and Drug Administration made it official Saturday, turning a thumbs-down to Lorqess (lorcaserin), the new diet drug by Arena Pharmaceuticals, because of concerns that it may cause tumors in rats and is marginally effective, according to the Pharmalot blog.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
A $1 billion effort by the Obama administration to relieve the physician shortage in rural America by subsidizing med school debt for young physicians is running up against a problem--not in attracting docs in the first place, but keeping them there once their initial three-to-five-year commitment is up.